Biological product filing citing a Frontiers in Medicine paper — Taysha Gene Therapies, 2026-05-06
Taysha Gene TherapiesTaysha Gene TherapiesNASDAQ TSHA
Filings SEC · Quote Yahoo cited a paper published in Frontiers in Medicine as a basis for its claims in a regulatory filing submitted to the U.S. Securities and Exchange CommissionU.S. Securities and Exchange Commission
Regulator · Website. The company read the manner in which it wrote the paper and the actual scope the paper demonstrated in sequence. It recorded where the stock price movement over the following month compared to past cases of the same type. This is a hindsight judgment written after knowing the results. The paper was read only up to the abstract.
The disclosure wrote the paper in the press release like this.
When a U.S. listed company has something to inform shareholders, it submits a form to the Securities and Exchange Commission called 8-K. The item number of the document submitted by Taysha Gene Therapies on 2026-05-06 was 2.02 Performance announcement · 9.01 Financial statements · Attached documents. The company cited a paper published in Frontiers in Medicine in the attached press release. The sentence citing the paper, copied verbatim from the original, is as follows.
The publication titled “ rAAV9 Vector Biodistribution in Nonhuman Primate Brain and Spinal Cord Following Lumbar Intrathecal Infusion ” was published in Frontiers in Medicine – Gene and Cell Therapy (DOI: 10.3389/fmed.2026.1819594) on April 28, 2026.
What readers should look at first is where the company placed the paper in the press release. Next, they should determine whether the paper supports the entire company claim or only a part of it. To answer the latter question, one must read the full paper. This article, which has read only the abstract, cannot provide an answer.
The scope of the paper discussed in the abstract is limited to this.
The paper title is rAAV9 vector biodistribution in nonhuman primate brain and spinal cord following lumbar intrathecal infusion and it was published in Frontiers in Medicine on 2026-04-29. The authors are affiliated with Université d'Artois · Southeastern University. The summary at the beginning of the paper is called abstract. This article has read only up to that point. This paragraph was rewritten by a person after filtering a draft written by a machine reading the abstract through numerical comparison, and thus differs in quality from a full-text review.
This study evaluated methods for delivering human-derived gene therapies to the central nervous system through animal experiments. Gene vectors were administered via intraventricular and intraspinal injection in 48 monkeys, and tissue distribution was measured. It was confirmed that the vector genes consistently distributed in the brain and spinal cord tissues according to the dosage. Intraspinal injection showed a distribution similar to intraventricular injection, but this study did not address long-term safety or human applicability.
The abstract does not answer; it remains in the main text and the appendix. This text, which does not go there, leaves the blank as it is. Readers compare the two citations above to determine which sentence in the abstract corresponds to the excerpt cited by the company.
One month later, the stock price was within the middle half of the sample.
The return excluding the portion attributable to market-wide movements is called excess return. Dates are recorded as trading days, counting only the days the stock market is open. In terms of the calendar, 20 trading days are approximately one month. The excess return on the day of the regulatory filing and for the following month are presented in the table below.
| Period | Excess return relative to the market | Meaning |
|---|---|---|
| 5 trading days before the filing | +8.3% | The extent to which it had already moved before the filing |
| regulatory filing day | −0.4% | filing day or the first trading day thereafter |
| +1~+5 trading day cumulative | −2.9% | one week |
| +1~+20 trading day cumulative | −16.9% | one month |
A bundle of past cases of the same type is called a sample. The position counted from the bottom is expressed as a percentile. The one-month excess return of -16.9% in this case is within the bottom 32% of the 142 samples, placing it in the lower half.
| sample scale (20 trading days) | Tenth from the bottom | Fourth from the bottom | median | top 25% | top 10% | this case |
|---|---|---|---|---|---|---|
| excess return | −31.9% | −20.1% | −6.9% | +5.5% | +19.5% | −16.9% |
Half of the sample falls between the two middle marks in the table. Check the table to see whether this case falls inside or outside of that range. The sample consists of cases where U.S.-listed companies cited papers in 8-K filings over the past decade. The company itself is excluded from the sample. The numbers listed here are historical facts, not rules to apply to future cases.
After the filing, the company submitted these documents.
After the filing date, the company submitted three 8-K filings. Only the item numbers are listed here. In 8-K filings without titles, the item numbers indicate the type of content. Whether it was an earnings announcement or a contract can be identified by the number. The details of what occurred are read in the original text via each link.
- 2026-06-02 8-K Item 5.07 — Results of Shareholder Meeting
- 2026-06-22 8-K Items 7.01, 8.01, 9.01 — Reg FD disclosure · Other events · Financial statements · Attached documents
- 2026-06-25 8-K Items 1.01, 8.01, 9.01 — Important contract signing · Other events · Financial statements · Attached documents
What this article does not answer
This article, which reads only abstracts, cannot answer how the paper re-examined what, using what methods, and up to what extent. How many times the paper cited by the company has been cited afterward can be rechecked via the citation count on OpenAlexOpenAlex
Data source · Website. What will be seen next is whether the company's next 8-K again cites the same paper.
Term Explanation
- 8-K
- A periodic report submitted to the Securities and Exchange Commission when a listed company in the United States has something to inform its shareholders. The type is indicated by item numbers such as performance, contracts, and executive changes. All events in this article are derived from this document.
- Excess return
- The remainder obtained by subtracting the overall market return from the stock return. It is used to observe the movement of the company itself by removing the portion where the market as a whole rises or falls.
- Trading day
- A date counted only when the stock market is open. Since weekends and holidays are excluded, 20 trading days correspond to approximately one month on the calendar.
- Sample and percentile
- A bundle of past cases of the same type is a sample, and the position from the bottom within it is expressed as a percentile. A percentile of 10 means that nine out of ten cases performed better than this case.
- Abstract
- A summary appearing at the beginning of a paper. The author writes in a few sentences what was done, how it was done, and what results were obtained. Without reading the full text, one cannot know the details and limitations of the methods.